2 results
Approved WMORecruiting
Two key questions remain to be answered to further elucidate the mechanism of action: 1) is the effect on glucose metabolism dose dependent in Type 2 diabetes patients? and 2) Does UAG decrease glucose concentrations during an oral glucose loadThis…
Approved WMORecruiting
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…